The CCK8 and subcutaneous xenograft mouse model displayed that Ipatasertib could reverse the contribution of COL8A1 to oxaliplatin resistance and remarkably reduce tumor volume and weight (Fig. 7K-O). This evidence concerns the gene COL8A1 and neoplasm.